Logo image of PGEN

PRECIGEN INC (PGEN) Stock Fundamental Analysis

NASDAQ:PGEN - Nasdaq - US74017N1054 - Common Stock - Currency: USD

3.64  +0.43 (+13.4%)

After market: 3.74 +0.1 (+2.75%)

Fundamental Rating

2

Taking everything into account, PGEN scores 2 out of 10 in our fundamental rating. PGEN was compared to 549 industry peers in the Biotechnology industry. Both the profitability and financial health of PGEN have multiple concerns. While showing a medium growth rate, PGEN is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year PGEN has reported negative net income.
PGEN had a negative operating cash flow in the past year.
PGEN had negative earnings in 4 of the past 5 years.
PGEN had a negative operating cash flow in each of the past 5 years.
PGEN Yearly Net Income VS EBIT VS OCF VS FCFPGEN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M -400M -500M

1.2 Ratios

With a Return On Assets value of -122.18%, PGEN is not doing good in the industry: 79.78% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -122.18%
ROE N/A
ROIC N/A
ROA(3y)-45.76%
ROA(5y)-43.42%
ROE(3y)-82.57%
ROE(5y)-117.47%
ROIC(3y)N/A
ROIC(5y)N/A
PGEN Yearly ROA, ROE, ROICPGEN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

1.3 Margins

PGEN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PGEN Yearly Profit, Operating, Gross MarginsPGEN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

3

2. Health

2.1 Basic Checks

PGEN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, PGEN has less shares outstanding
PGEN has less shares outstanding than it did 5 years ago.
There is no outstanding debt for PGEN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
PGEN Yearly Shares OutstandingPGEN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
PGEN Yearly Total Debt VS Total AssetsPGEN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

Based on the Altman-Z score of -26.35, we must say that PGEN is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of PGEN (-26.35) is worse than 86.52% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -26.35
ROIC/WACCN/A
WACC9.78%
PGEN Yearly LT Debt VS Equity VS FCFPGEN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

A Current Ratio of 2.71 indicates that PGEN has no problem at all paying its short term obligations.
With a Current ratio value of 2.71, PGEN is not doing good in the industry: 67.58% of the companies in the same industry are doing better.
PGEN has a Quick Ratio of 2.71. This indicates that PGEN is financially healthy and has no problem in meeting its short term obligations.
PGEN has a worse Quick ratio (2.71) than 65.57% of its industry peers.
Industry RankSector Rank
Current Ratio 2.71
Quick Ratio 2.71
PGEN Yearly Current Assets VS Current LiabilitesPGEN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 24.39% over the past year.
PGEN shows a decrease in Revenue. In the last year, the revenue decreased by -1.14%.
Measured over the past years, PGEN shows a very negative growth in Revenue. The Revenue has been decreasing by -46.64% on average per year.
EPS 1Y (TTM)24.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10%
Revenue 1Y (TTM)-1.14%
Revenue growth 3Y-35.01%
Revenue growth 5Y-46.64%
Sales Q2Q%19.39%

3.2 Future

Based on estimates for the next years, PGEN will show a very strong growth in Earnings Per Share. The EPS will grow by 31.44% on average per year.
PGEN is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 158.91% yearly.
EPS Next Y-2.95%
EPS Next 2Y37.27%
EPS Next 3Y41.46%
EPS Next 5Y31.44%
Revenue Next Year232.31%
Revenue Next 2Y434.53%
Revenue Next 3Y303.56%
Revenue Next 5Y158.91%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
PGEN Yearly Revenue VS EstimatesPGEN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M
PGEN Yearly EPS VS EstimatesPGEN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 1 -1 -2 -3

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PGEN. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PGEN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PGEN Price Earnings VS Forward Price EarningsPGEN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PGEN Per share dataPGEN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.1 -0.2 -0.3

4.3 Compensation for Growth

A more expensive valuation may be justified as PGEN's earnings are expected to grow with 41.46% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y37.27%
EPS Next 3Y41.46%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PGEN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PRECIGEN INC

NASDAQ:PGEN (8/21/2025, 8:00:00 PM)

After market: 3.74 +0.1 (+2.75%)

3.64

+0.43 (+13.4%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-12 2025-08-12/amc
Earnings (Next)11-12 2025-11-12/amc
Inst Owners67.11%
Inst Owner Change1.56%
Ins Owners3.31%
Ins Owner Change5.64%
Market Cap1.08B
Analysts78
Price Target6.12 (68.13%)
Short Float %10.81%
Short Ratio4.48
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3.74%
Min EPS beat(2)-6.73%
Max EPS beat(2)14.22%
EPS beat(4)1
Avg EPS beat(4)-1.68%
Min EPS beat(4)-10.29%
Max EPS beat(4)14.22%
EPS beat(8)1
Avg EPS beat(8)-10.67%
EPS beat(12)2
Avg EPS beat(12)-34.53%
EPS beat(16)5
Avg EPS beat(16)-22.22%
Revenue beat(2)2
Avg Revenue beat(2)94.41%
Min Revenue beat(2)25.88%
Max Revenue beat(2)162.94%
Revenue beat(4)2
Avg Revenue beat(4)37.5%
Min Revenue beat(4)-25.25%
Max Revenue beat(4)162.94%
Revenue beat(8)2
Avg Revenue beat(8)1.81%
Revenue beat(12)2
Avg Revenue beat(12)-12.53%
Revenue beat(16)2
Avg Revenue beat(16)-30.35%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-3.34%
EPS NY rev (1m)0%
EPS NY rev (3m)-13.68%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)33.33%
Revenue NY rev (1m)0%
Revenue NY rev (3m)23.46%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 249.91
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.31
EYN/A
EPS(NY)-0.04
Fwd EYN/A
FCF(TTM)-0.23
FCFYN/A
OCF(TTM)-0.22
OCFYN/A
SpS0.01
BVpS-0.02
TBVpS-0.08
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -122.18%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-45.76%
ROA(5y)-43.42%
ROE(3y)-82.57%
ROE(5y)-117.47%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 134.85%
Cap/Sales 80.6%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.71
Quick Ratio 2.71
Altman-Z -26.35
F-Score5
WACC9.78%
ROIC/WACCN/A
Cap/Depr(3y)86.13%
Cap/Depr(5y)70.81%
Cap/Sales(3y)87.22%
Cap/Sales(5y)63.93%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)24.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10%
EPS Next Y-2.95%
EPS Next 2Y37.27%
EPS Next 3Y41.46%
EPS Next 5Y31.44%
Revenue 1Y (TTM)-1.14%
Revenue growth 3Y-35.01%
Revenue growth 5Y-46.64%
Sales Q2Q%19.39%
Revenue Next Year232.31%
Revenue Next 2Y434.53%
Revenue Next 3Y303.56%
Revenue Next 5Y158.91%
EBIT growth 1Y0.61%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year19.56%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y7.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y9.67%
OCF growth 3YN/A
OCF growth 5YN/A